|
Re: Slight increase in short interest up to November 15th +15,066 shares
|
2
|
Resverlogix Corp.
|
Nov 21, 2018 03:47AM
|
|
Re: Apabetalone downregulates factors and pathways associated with vascular calcification
|
2
|
Resverlogix Corp.
|
Nov 21, 2018 03:58AM
|
|
Re: Apabetalone downregulates factors and pathways associated with vascular calcification
|
2
|
Resverlogix Corp.
|
Nov 21, 2018 11:44AM
|
|
Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
3
|
Zenith Epigenetics
|
Nov 22, 2018 01:11PM
|
|
Re: What is Mr. Market saying about RVX?
|
3
|
Resverlogix Corp.
|
Nov 25, 2018 07:47PM
|
|
Re: What is Mr. Market saying about RVX?
|
6
|
Resverlogix Corp.
|
Nov 26, 2018 11:39AM
|
|
Re: What is Mr. Market saying about RVX?
|
5
|
Resverlogix Corp.
|
Nov 26, 2018 11:47AM
|
|
Re: What is Mr. Market saying about RVX?
|
4
|
Resverlogix Corp.
|
Nov 26, 2018 12:34PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
|
3
|
Resverlogix Corp.
|
Nov 28, 2018 09:42AM
|
|
Re: Remembering Relypsa
|
6
|
Resverlogix Corp.
|
Nov 30, 2018 02:34AM
|
|
Re: The Pfizer connection...
|
5
|
Resverlogix Corp.
|
Nov 30, 2018 10:06PM
|
|
Re: Pointing in the right direction & bogus Lilly
|
5
|
Resverlogix Corp.
|
Dec 01, 2018 02:59PM
|
|
Re: Patient Enrollment Modeling
|
5
|
Resverlogix Corp.
|
Dec 02, 2018 12:58PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
4
|
Resverlogix Corp.
|
Dec 03, 2018 08:40PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex
|
4
|
Resverlogix Corp.
|
Dec 04, 2018 11:32PM
|
|
Re: The runway is clear....
|
8
|
Resverlogix Corp.
|
Dec 06, 2018 01:05PM
|
|
Re: Top-line vs. Full Detailed Clinical Trial Results
|
2
|
Resverlogix Corp.
|
Dec 07, 2018 05:13PM
|
|
Re: Top-line vs. Full Detailed Clinical Trial Results
|
2
|
Resverlogix Corp.
|
Dec 08, 2018 12:40AM
|
|
Re: The runway is clear....
|
5
|
Resverlogix Corp.
|
Dec 08, 2018 03:02PM
|
|
Re: The runway is clear....
|
5
|
Resverlogix Corp.
|
Dec 08, 2018 04:09PM
|
